Denali Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2015
Net Income	-145.22	-325.99	-290.58	71.14	-197.61	Upgrade
Depreciation & Amortization	16.73	10.38	8.59	8.53	7.99	Upgrade
Share-Based Compensation	108.1	99.85	85.25	50.35	38.38	Upgrade
Other Operating Activities	-337.6	-28.96	-14.65	286.13	-0.33	Upgrade
Operating Cash Flow	-357.99	-244.72	-211.39	416.15	-151.58	Upgrade
Capital Expenditures	-12.94	-17.83	-8.5	-3.1	-17.92	Upgrade
Change in Investments	262.25	-123.55	-13.13	-620.11	165.63	Upgrade
Investing Cash Flow	249.31	-141.39	-21.63	-623.21	147.71	Upgrade
Share Issuance / Repurchase	17.82	310.67	19.35	634.75	6.19	Upgrade
Financing Cash Flow	17.82	310.67	19.35	634.75	6.19	Upgrade
Net Cash Flow	-90.86	-75.43	-213.67	427.7	2.33	Upgrade
Free Cash Flow	-370.93	-262.55	-219.89	413.06	-169.5	Upgrade
Free Cash Flow Margin	-112.22%	-242.06%	-451.88%	123.06%	-635.34%	Upgrade
Free Cash Flow Per Share	-2.70	-2.09	-1.81	3.44	-1.77	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).